Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer

BACKGROUND: Clinicopathological and molecular features of responders to nivolumab for advanced gastric cancer (AGC) are not well understood. METHODS: Patients (pts) with AGC who were treated with nivolumab after two or more chemotherapy regimens in a single institution from September 2017 to May 201...

Descripción completa

Detalles Bibliográficos
Autores principales: Mishima, Saori, Kawazoe, Akihito, Nakamura, Yoshiaki, Sasaki, Akinori, Kotani, Daisuke, Kuboki, Yasutoshi, Bando, Hideaki, Kojima, Takashi, Doi, Toshihiko, Ohtsu, Atsushi, Yoshino, Takayuki, Kuwata, Takeshi, Tsuji, Akihito, Shitara, Kohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357506/
https://www.ncbi.nlm.nih.gov/pubmed/30704511
http://dx.doi.org/10.1186/s40425-019-0514-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357506/
https://www.ncbi.nlm.nih.gov/pubmed/30704511
http://dx.doi.org/10.1186/s40425-019-0514-3

Ejemplares similares